Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around $2.9 billion).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback